A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibitor

被引：0
|
作者：
Wang, J. [1 ]
Shen, Y. [1 ]
Chen, J. [2 ]
Chen, X. [3 ]
Guan, Q. [4 ]
Liu, Q. [5 ]
Xu, J. [6 ]
Xu, Y. [7 ]
Zhang, B. [8 ]
Zhang, H. [9 ]
Zhu, Y. [10 ]
Zhang, Y. [11 ]
机构：
[1] Jiangsu Canc Hosp, Gynecol, Nanjing, Peoples R China
[2] Second Peoples Hosp Changzhou, Gynecol, Changzhou, Jiangsu, Peoples R China
[3] First Peoples Hosp Yancheng, Gynecol, Yancheng, Peoples R China
[4] Jiangsu Hosp Tradit Chinese Med, Gynecol, Nanjing, Peoples R China
[5] Nanjing Med Univ, Jiangning Hosp, Gynecol, Nanjing, Peoples R China
[6] Subei Peoples Hosp Jiangsu Prov, Gynecol, Yangzhou, Jiangsu, Peoples R China
[7] First Peoples Hosp Changzhou, Gynecol, Changzhou, Jiangsu, Peoples R China
[8] Fourth Peoples Hosp Xuzhou, Xuzhou Cent Hosp, Gynecol, Xuzhou, Jiangsu, Peoples R China
[9] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Gynecol, Nanjing, Peoples R China
[10] Xuzhou Third Peoples Hosp, Xuzhou Canc Hosp, Gynecol, Xuzhou, Jiangsu, Peoples R China
[11] First Peoples Hosp Lianyungang, Gynecol, Lianyungang, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
202P
引用
收藏
页码：S1513 / S1513
页数：1
相关论文
共 50 条
  • [31] Biomarker testing to guide first-line PARP inhibitor maintenance for patients with advanced ovarian cancer after response to first-line platinum chemotherapy: A cost-effectiveness study
    Fan, Lin
    Elsea, David
    Muston, Dominic
    Mihai, Adela
    Monberg, Matthew
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S195 - S195
  • [32] Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
    Zhang, Yan
    Xu, Junying
    Wang, Qiong
    Ling, Guohong
    Mao, Yong
    Cai, Maohuai
    Yang, Yang
    Mei, Jingfeng
    Han, Zhengxiang
    Feng, Jifeng
    Wu, Yuan
    Shi, Lin
    Wen, Shaodi
    Shen, Bo
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [33] An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer
    Rose, Peter G.
    Monk, Bradley J.
    Provencher, Diane
    Hartney, Jean
    Legenne, Philippe
    Lane, Stephen
    GYNECOLOGIC ONCOLOGY, 2011, 120 (01) : 38 - 42
  • [34] Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naive Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
    Drew, Yvette
    Kim, Jae-Weon
    Penson, Richard T.
    O'Malley, David M.
    Parkinson, Christine
    Roxburgh, Patricia
    Plummer, Ruth
    Im, Seock-Ah
    Imbimbo, Martina
    Ferguson, Michelle
    Rosengarten, Ora
    Steeghs, Neeltje
    Kim, Min Hwan
    Gal-Yam, Einav
    Tsoref, Daliah
    Kim, Jae-Hoon
    You, Benoit
    De Jonge, Maja
    Lalisang, Roy
    Gort, Eelke
    Bastian, Sara
    Meyer, Kassondra
    Feeney, Laura
    Baker, Nigel
    Ah-See, Mei-Lin
    Domchek, Susan M.
    Banerjee, Susana
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 50 - 62
  • [35] The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third- line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
    Secord, A. Alvarez
    Lewin, S. N.
    Murphy, C. G.
    Cecere, S. C.
    Barquin, A.
    Galvez-Montosa, F.
    Mathews, C. A.
    Konecny, G. E.
    Ray-Coquard, I.
    Oakni, A.
    Perez, M. J. Rubio
    Bonaventura, A.
    Diver, E. J.
    Ayuk, S. -M
    Wang, Y.
    Corr, B. R.
    Salutari, V.
    ANNALS OF ONCOLOGY, 2025, 36 (03) : 321 - 330
  • [36] Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study
    Ding, X.
    Zhang, W.
    You, R.
    Zou, X.
    Wang, Z.
    Ouyang, Y-F.
    Liu, Y-L.
    Peng, L.
    You-Ping, L.
    Duan, C-Y.
    Yang, Q.
    Lin, C.
    Yulong, X.
    Chen, S-Y.
    Gu, C-M.
    Huang, P. Y.
    Hua, Y.
    Chen, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S846 - S846
  • [37] Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study
    Liu, Wenlou
    Wang, Hongmei
    Zhao, Yang
    Ge, Yan
    Tang, Juangjuang
    Cao, Menghan
    Matsas, Silvio
    Breadner, Daniel Adam
    Qin, Xiaobing
    Han, Zhengxiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04)
  • [38] Clinical study on the second-line treatment of advanced esophageal squamous cell carcinoma with camrelizumab combined with apatinib and irinotecan: A single-arm, multicenter, phase II study
    He, Yifu
    Li, Chenghui
    Zhang, Fenglin
    Hu, Bing
    Sun, Yubei
    Xia, Xiaoyang
    Zhang, Yanshun
    Wang, Gang
    Xu, Tengyun
    Duan, Aixiong
    Wu, Shusheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [39] Safety and efficacy of endostar combined with platinum-based chemotherapy in the first-line treatment of recurrence and metastatic cervical cancer: A single-arm, prospective phase II study
    Zhou, J.
    Wang, L.
    Zhuang, H.
    Qin, S.
    Xu, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S754 - S754
  • [40] Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study
    Rubio, Maria Jesus
    Manzano, Aranzazu
    de Sande, Luis Miguel
    Estevez-Garcia, Purificacion
    Gordon, Maria del Mar
    de Prado, Diego Soto
    de Aranguiz, Blanca Hernando Fernandez
    Guerra-Alia, Eva M.
    Carbo-Bague, Anna
    Romero, Ignacio
    Corbellas, Miguel
    Gonzalez-Haba, Alba
    Robles-Barraza, Carlos E.
    Martinez-Garcia, Jeronimo
    Gonzalez-Martin, Antonio
    BMC CANCER, 2024, 24 (01)
12345